<div id="readability-page-1"><p>Vericel (NASDAQ:VCEL - Get Free Report) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03, FiscalAI reports. Vericel had a return on equity of 5.17% and a net margin of 5.98%.The business had revenue of $68.43 million for the quarter, compared to the consensus estimate of $63.68 million. During the same quarter in the prior year, the business posted ($0.23) EPS. The business's revenue for the quarter was up 30.1% on a year-over-year basis.</p><ul><li>5 medical stocks growing earnings by triple digits</li></ul><p>Here are the key takeaways from Vericel's conference call:</p><ul>   <li><strong>Record Q1 financials</strong> — total revenue of $68.4M (+30% YoY), MACI $56.4M (+22%), gross margin ~72%, adjusted EBITDA ~ $9.6M (tripled YoY), and free cash flow $15.1M with ~$211M cash and investments.</li>   <li><strong>Raised 2026 guidance</strong> — total revenue guidance increased by $10M to $326M–$336M; MACI guidance lifted to $282M–$288M and Burn Care to $44M–$48M, with expected NexoBrid BARDA procurement revenue of ~$5M–$6M in H2.</li>   <li><strong>Commercial momentum for MACI</strong> — expanded sales force drove record biopsies, accelerating implants and deeper per‑surgeon penetration; MACI Arthro trainees now account for &gt;50% of implants and early investigator data suggests less post‑op pain and faster recovery.</li>   <li><strong>Capacity and international expansion</strong> — FDA approved commercial manufacturing at the new Burlington facility to support U.S. growth and enable a planned MACI marketing submission in the U.K. later this year (targeting a possible 2027 launch).</li>   <li>Management remains prudent — full‑year outlook assumes no implicit MACI acceleration, accounts for incremental costs (new facility, salesforce expansion, MACI ankle trial and life‑cycle investments), and future BARDA optional awards and conversion improvements remain uncertain.</li> </ul><h2>Vericel Stock Down 4.5%</h2><p>NASDAQ:VCEL traded down $1.65 during mid-day trading on Thursday, reaching $35.13. 1,192,576 shares of the stock were exchanged, compared to its average volume of 538,314. The company has a 50 day simple moving average of $33.93 and a 200-day simple moving average of $36.20. The stock has a market capitalization of $1.79 billion, a P/E ratio of 113.32 and a beta of 1.15. Vericel has a 1 year low of $28.95 and a 1 year high of $45.97. </p><h2>Analysts Set New Price Targets</h2><p>A number of research analysts have recently commented on VCEL shares. Leerink Partners  reiterated an &#34;outperform&#34; rating and issued a $46.00 price objective on shares of Vericel in a report on Tuesday, March 10th. Truist Financial dropped their price objective on Vericel from $48.00 to $42.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, April 15th. Wall Street Zen upgraded Vericel from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, March 28th. Finally, HC Wainwright raised their price target on Vericel from $60.00 to $64.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating and three have issued  a Hold rating to the stock. Based on data from MarketBeat, Vericel currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $55.40.</p><p><b>Get Our Latest Stock Analysis on Vericel</b></p><h2>Insider Transactions at Vericel</h2><p>In related news, insider Jonathan Mark Hopper sold 3,472 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $121,520.00. Following the transaction, the insider owned 75,556 shares in the company, valued at $2,644,460. This trade represents a 4.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC purchased a new position in shares of  Vericel in the 4th quarter valued at approximately $300,000.  Empowered Funds LLC purchased a new position in shares of  Vericel in the 4th quarter valued at approximately $58,000.  XTX Topco Ltd purchased a new position in shares of  Vericel in the 4th quarter valued at approximately $668,000.  Susquehanna Portfolio Strategies LLC grew its stake in shares of  Vericel by 43.5% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 135,054 shares of the biotechnology company's stock valued at $4,863,000 after purchasing an additional 40,948 shares during the last quarter.  Finally, Osterweis Capital Management Inc. grew its stake in shares of  Vericel by 4.8% in the 4th quarter. Osterweis Capital Management Inc. now owns 322,975 shares of the biotechnology company's stock valued at $11,630,000 after purchasing an additional 14,920 shares during the last quarter. </p><h2>About Vericel</h2> (Get Free Report)<p>Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company's expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.  </p><p>Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Vericel</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkNFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkNFTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vericel Right Now?</h2><p>Before you consider Vericel, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.</p><p>While Vericel currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VCEL

<p>Vericel (NASDAQ:VCEL) reported quarterly earnings of ($0.12) EPS, beating estimates by $0.03. Revenue reached $68.43 million, exceeding expectations of $63.68 million, marking a 30.1% year-over-year increase. The company raised its 2026 revenue guidance to $326M–$336M. Despite strong financials, Vericel's stock fell 4.5% to $35.13. Analysts maintain a "Moderate Buy" rating with an average price target of $55.40. Insider Jonathan Mark Hopper sold shares, reducing his stake by 4.39%.</p>

Market Beat

Vericel

Truist Financial

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS